Was 2025 over-inflated? Wolfe downgraded Enterprise Products Partners (EPD.US) to "underperform" - valuation is too high and advantages are no longer present.
Wolfe Research published a research report, downgrading midstream energy company Enterprise Products Partners from "in line with peers" to "underperforming peers," while giving a target price of $31.
Wolfe Research released a research report, downgrading the rating of midstream energy company Enterprise Products Partners (EPD.US) from "in line with industry" to "underperform," while setting a target price of $31. Wolfe pointed out that the company's performance in 2025 was very weak, but the stock price has shown a strong rally, leading to its current valuation being significantly higher than industry peers.
Analyst Keith Stanley believes that Enterprise Products no longer has the confidence to enjoy a premium valuation over midstream energy Master Limited Partnerships (MLPs) in the industry. The reasons being, the company's performance in 2025 confirmed that its business defensiveness is not outstanding; its current balance sheet situation is in line with most industry peers, and its previous competitive advantage has been greatly weakened; its core Permian Basin natural gas liquids growth business is facing intense market competition, with the risk of industry oversupply increasing.
Stanley also stated that he is cautiously optimistic about the eventual recovery of the oil market in 2026, as well as the alleviation of transportation bottlenecks for natural gas in the Permian Basin these two trends would benefit stocks related to the Permian Basin. However, he emphasized that after the significant stock price increase in 2025, Enterprise Products' stock price has much less room to grow compared to its industry peers. Additionally, considering the company's historically conservative capital allocation strategy, the long-awaited stock buyback program may disappoint investors in the end.
Related Articles

SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.

CHINA ITS (01900) subsidiary redeeming private equity fund interests
SUNHO BIO-B(02898): Jiang Xiaoling appointed as Chief Executive Officer and Chief Scientific Officer

RIMAG GROUP (02522) has issued 6.13 million H shares of bonus shares.

CHINA ITS (01900) subsidiary redeeming private equity fund interests

RECOMMEND

Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026

Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026

Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026


